MAPT and Alzheimer disease: MiR-23b-3p exhibits neuroprotection by inhibiting tau phosphorylation, alleviating AD-like symptoms in AD model mice, and interrupting GSK-3β-dependent tau phosphorylation at Ser396 and Ser404 in vivo [63].